Department of Medical Oncology, University Medical Center Utrecht.
Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Am J Clin Oncol. 2021 Jul 1;44(7):315-324. doi: 10.1097/COC.0000000000000823.
Location of the primary tumor has prognostic value and predicts the effect of certain therapeutics in synchronous metastatic colorectal cancer. We investigated whether the association between primary tumor resection (PTR) and overall survival (OS) also depends on tumor location.
Data on synchronous metastatic colorectal cancer patients from the Netherlands Cancer Registry (n=16,106) and Surveillance, Epidemiology, and End Results (SEER) registry (n=19,584) were extracted. Cox models using time-varying covariates were implemented. Median OS for right-sided colon cancer (RCC), left-sided colon cancer, and rectal cancer was calculated using inverse probability weighting and a landmark point of 6 months after diagnosis as reference.
The association between PTR and OS was dependent on tumor location (P<0.05), with a higher median OS of upfront PTR versus upfront systemic therapy in Netherlands Cancer Registry (NCR) of 1.9 (95% confidence interval: 0.9-2.8), 4.3 (3.3-5.6), and 3.4 (0.6-7.6) months in RCC, left-sided colon cancer and rectal cancer, respectively. In SEER data, the difference was 6.0 (4.0-8.0), 8.0 (5.0-10.0), and 10.0 (7.0-13.0) months, respectively. Hazard plots indicate a higher hazard of death 2 to 3 months after PTR in RCC.
Upfront PTR is associated with improved survival regardless of primary tumor location. Patients with RCC appear to have less benefit because of higher mortality during 2 to 3 months after PTR.
原发肿瘤的位置具有预后价值,并预测同步转移性结直肠癌某些治疗方法的效果。我们研究了原发肿瘤切除(PTR)与总生存期(OS)之间的关联是否也取决于肿瘤位置。
从荷兰癌症登记处(n=16106)和监测、流行病学和最终结果(SEER)登记处(n=19584)提取了同步转移性结直肠癌患者的数据。使用时变协变量的 Cox 模型进行了分析。使用逆概率加权和诊断后 6 个月的标志点计算右半结肠癌(RCC)、左半结肠癌和直肠癌的中位 OS。
PTR 与 OS 之间的关联取决于肿瘤位置(P<0.05),与荷兰癌症登记处(NCR)中的 upfront PTR 相比, upfront 系统治疗的中位 OS 分别在 RCC、左半结肠癌和直肠癌中提高了 1.9(95%置信区间:0.9-2.8)、4.3(3.3-5.6)和 3.4(0.6-7.6)个月。在 SEER 数据中,差异分别为 6.0(4.0-8.0)、8.0(5.0-10.0)和 10.0(7.0-13.0)个月。危险图表明,RCC 患者在 PTR 后 2 至 3 个月的死亡风险更高。
无论原发肿瘤位置如何, upfront PTR 均与生存改善相关。RCC 患者的获益似乎较低,因为 PTR 后 2 至 3 个月死亡率较高。